California-based nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS) has unveiled exciting new findings at the Psychedelic Science 2017 conference, which indicate that the use of MDMA for PTSD may truly be in our midst.
MAPS revealed that out of the 107 participants in their trials, 67 percent of participants reported that their PTSD was no longer showcasing symptoms against only 23% of the placebo group after one year. The clinical trial group underwent two-three treatments with MDMA and backed it with guidance from mental health professionals.
The FDA has approved them to move on to Phase III trials, which will expand the number of participants in their study. They've also received $5 Million in donations by soap company Dr. Bronners, which will help aid their research.
While it is still hard to say for sure, the road for MDMA to treat PTSD and other mental health issues like anxiety seem to be turning into reality right before our eyes.